Director – Nonclinical Toxicology Operations
Nurix Therapeutics
Director – Nonclinical Toxicology Operations
Nurix Therapeutics
Drug discovery targeting ubiquitin E3 ligases
Director, Nonclinical Toxicology Operations
Nurix Therapetics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
Position Summary:
Nurix Therapeutics is seeking a Director of Preclinical Safety and Toxicology Operations to drive planning and execution of nonclinical safety and toxicology activities within our Research and Early Development division. The role will be responsible for operations activities including owning timelines, budgets, contracts, and cross-functional coordination for a portfolio of targeted protein degradation programs. The ideal candidate will be adept at partnering closely with subject matter experts, preclinical Project Leads, clinical Asset Team Leaders, and the SVP of Preclinical Toxicology who will provide oversight and scientific direction.
The role has two complementary halves. The first is operational support to the nonclinical Safety and Toxicology function — helping study directors and toxicology leads scope and design studies, selecting and managing CROs, negotiating and administering contracts, and keeping study execution on schedule and on budget. The second is program-level project management for drug discovery projects as they transition from late lead optimization through IND filing, integrating chemistry, DMPK, pharmacology, safety, CMC, and regulatory timelines into a single credible plan.
You will thrive here if you are highly organized, scientifically fluent, comfortable holding teams and stakeholders to a schedule, and energized by turning complex, interdependent work into clear milestones and decisions.
Key Responsibilities:
Toxicology study support and vendor management
Program management, late lead optimization to IND
Cross-functional leadership and process
Qualifications:
Education
Experience
Skills and attributes
Reporting and Location
Fit with Nurix Culture and Values
Salary Range: $220,700 - $252,667
Location: Brisbane, CA - Onsite
Drug discovery targeting ubiquitin E3 ligases
Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.
Explore more opportunities at Nurix Therapeutics